Navigation Links
Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses
Date:8/22/2010

New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposuresuggesting the approach holds promise for treating accidental infections in laboratory or hospital settings.

The research, which appears in today's online edition of the journal Nature Medicine, was conducted by the U.S. Army Medical Research Institute of Infectious Diseases in collaboration with AVI BioPharma, a Washington-based biotechnology firm.

Working with a class of compounds known as antisense phosphorodiamidate morpholino oligomers, or PMOs, scientists first performed a series of studies with mouse and guinea pig models of Ebola to screen various chemical variations. They arrived at a therapy known as AVI-6002, which demonstrated a survival rate of better than 90 percent in animals treated either pre- or post-exposure.

Encouraged by these results, the team conducted "proof of concept" studies in which 9 rhesus monkeys were challenged with lethal Ebola virus. Treatment was initiated 30-60 minutes after exposure to the virus. In these studies, 5 of 8 monkeys survived, while the remaining animal was untreated. Further experiments, including a multiple-dose evaluation, also yielded promising results, with 3 of 5 monkeys surviving in each of the AVI-6002 treatment groups when they received a dose of 40 mg per kg of body weight.

According to first author Travis K. Warren of USAMRIID, antisense drugs are useful against viral diseases because they are designed to enter cells and eliminate viruses by preventing their replication. The drugs act by blocking critical viral genetic sequences, essentially giving the infected host time to mount an immune response and clear the virus.

Ebola and Marburg cause hemorrhagic fever with case fatality rates as high as 90 percent in humans. The v
'/>"/>

Contact: Caree Vander Linden
caree.vander-linden@amedd.army.mil
US Army Medical Research Institute of Infectious Diseases
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Novel bee venom derivative forms a nanoparticle smart bomb to target cancer cells
2. UM researcher identifies novel treatment for pain in sickle cell disease
3. Novel microfluidic HIV test is quick and cheap
4. NIH-supported study finds novel pathway may open doors for new blood pressure treatments
5. Novel protein essential for successful pregnancy
6. UT Southwestern researchers use novel sperm stem-cell technique to produce genetically modified rats
7. Novel processing technologies developed for extending use of oats in gluten-free diet
8. Novel strategy for generating induced pluripotent stem cells for clinical use is safe and efficient
9. International research team discovers novel genes influencing kidney disease risk
10. Researchers use novel nanoparticle vaccine to cure type 1 diabetes in mice
11. Pitt-led international study identifies human enzyme that breaks down potentially toxic nanomaterials, opens door to novel drug delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... with undiagnosed, suspected genetic conditions, a certain type of ... diagnostic yield than traditional molecular diagnostic methods, according to ... is being released to coincide with the American Society ... sequences the protein­coding region of the genome (the complete ... cell or organism), has been rapidly applied in research ...
(Date:10/16/2014)... on the human body. Battles are won, lost ... cancer, this stalemate—known as tumor dormancy—can last up ... phenomena that is poorly understood. , A ... Salvatore Torquato, a Professor of Chemistry at Princeton ... dormancy and the switch to a malignant state. ...
(Date:10/16/2014)... Virus causes severe respiratory tract infections and worldwide ... Scientists at VIB and Ghent University have succeeded ... this common virus infection. , Xavier Saelens ... paves the way for the development of a ... that causes suffering in numerous small children and ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
... of Americans are obese, and these individuals often experience ... cardiovascular problems. In response to the so-called "obesity epidemic," ... health outcomes of obese individuals through diet and exercise. ... certain exercises that benefit obese men may not have ...
... Institute for Biological Studies has received a $42 million ... Center for Genomic Medicine (HCGM), a research center dedicated ... chronic human diseases. The award, from the Leona ... interdisciplinary research that paves the way to new therapies ...
... SAN DIEGO , Jan. 23, 2013 ... discovery and development of innovative treatments for cardiovascular ... and Trademark Office (USPTO) issued a notice of ... claims that cover methods for identifying compounds that ...
Cached Biology News:Women must do more to reap same positive health outcomes as men, MU research suggests 2Salk Institute awarded historic $42 million grant from the Helmsley Charitable Trust 2Salk Institute awarded historic $42 million grant from the Helmsley Charitable Trust 3Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office 2Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office 3
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
(Date:10/20/2014)... Rochelle, Virginia (PRWEB) October 20, 2014 ... of NDA Partners LLC, announced today that Ellen ... and legal support for the pharmaceutical industry, has ... and manager of its legal services practice. ... reports and expert witness and testimony, to top ...
(Date:10/19/2014)... October 19, 2014 The Latin American ... market in Latin America with analysis and forecast of ... 2013, and is expected to reach $2,366.8 million by ... 2018. , Browse through the TOC of the Latin ... of the in-depth analysis provided. It also provides a ...
(Date:10/19/2014)... 19, 2014 NextCODE Health, which enables clinicians and ... real time, today announced the launch of its new genomic ... at the American Society of Human Genetics (ASHG) annual meeting ... sign up and apply for free beta access, visit ... benefits can be viewed here . The ...
Breaking Biology Technology:PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3
... Pharmaceuticals, Inc.,(Nasdaq: AMLN ) will be presenting at ... 2008 at 10:00 a.m. PT in Las Vegas. Michael,York, ... providing a corporate overview., The live presentation and ... made available following the event. The webcast and,recording will ...
... Agreement expands Dermagraft presence within government channels, ... May 7 Advanced,BioHealing, Inc. (ABH) and ... on the promotion of Dermagraft(R) within the ... of the agreement,Regenesis will provide its specialized ...
... Demonstrate Abbott,s Most Advanced NNR Candidate ABT-089 ... Adults With ADHD, ABBOTT PARK, Ill., May ... leading scientists will present new Phase II data ... agonist, is a,potentially effective and safe treatment for ...
Cached Biology Technology:Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R) 2Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R) 3Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder 2Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder 3Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder 4Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder 5
... Buffer is a convenient, premixed, ... samples and Perfect RNA Markers. ... no dilution and is suitable ... Simply mix equal volumes of ...
... cells were cultured in DMEM and harvested at ... to keep the antigens in their native forms, ... are arrayed on a 12-well (5 mm) adhesive ... to enhance cellular attachment and to minimize background ...
... CopyControl™ vector can be induced prior to ... provide the stability of single-copy BACs with ... other cloning vectors. The kits provide the ... insert size screening system) necessary to create ...
... 3T3 cells were cultured in DMEM with 4 ... of growth. In order to keep the ... in acetone-methanol. The cells are arrayed on ... each wells surface specifically treated to enhance cellular ...
Biology Products: